IL Dong Pharmaceutical Group Enters Functional Skincare Market, Forms JV with Nine & Company
Predicted impact: Medium
JV with Ildong already reported in recent items; size unknown versus market value of about ₩90.6B.
IL Dong Pharmaceutical일동제약
249420 · KOSPI · ₩249420 · 일동제약
₩12,790▲ ₩140 (1.11%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −46.26%
- Market cap
- ₩405B
- Enterprise value
- ₩467B
- P/E
- 9.3×
- P/B
- 1.6×
- Dividend yield
- 1.6%
- ROE
- 16.9%
- Net margin
- 7.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−71.6% from the high
₩11,250Today: ₩12,640 – ₩13,040₩45,050
Returns
- 1W−4.8%
- 1M−9.0%
- 3M+5.3%
- 6M−53.2%
- YTD−66.8%
- 1Y−46.3%
- Volume today
- 91,719
- 0.7× the 20-day average
- Traded today
- ₩1.2B
- Listed shares
- 31,638,252
- EPS (12 months)
- ₩1,378
- Earnings yield 10.8%
AI research · InitiationIL Dong Pharmaceutical: Returns to Profit After Years of Losses, While the Share Price Falls 38.4% in a YearThe data shows a company that has recovered from deep losses to modest operating profit, with a trailing ROE of 20.8% and multiples that are lower than its own recent history and its peers.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Two news reports cover a new business venture, and the filing is routine. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-7.6% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
IL Dong Pharmaceutical stock overview
IL Dong Pharmaceutical (일동제약, KRX: 249420) is listed on KOSPI, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals, pharmaceutical raw materials, health supplements, and special nutritional foods. Its shares closed at ₩12,790 on Oct 28, 2026, up 1.11% on the day, giving it a market value of ₩405B.
Key facts
- Market cap
- ₩405B
- Sector
- Biotech & Pharma
- Latest price change
- +1.11%
- As of
- Oct 28, 2026
- Main business
- The company manufactures and sells pharmaceuticals, pharmaceutical raw materials, health supplements, and special nutritional foods.
Quick answers about IL Dong Pharmaceutical
- What does IL Dong Pharmaceutical do?
- The company manufactures and sells pharmaceuticals, pharmaceutical raw materials, health supplements, and special nutritional foods. Its main pharmaceutical products include active vitamin products such as Aronamin-series, the antibiotic Furamarin, and other prescription and over-the-counter medicines. Products are sold through wholesalers, retailers, clinics, and general hospitals in Korea and abroad, and the company operates production facilities in Anseong and Cheongju, South Korea.
- What is the market cap of IL Dong Pharmaceutical?
- The market capitalisation of IL Dong Pharmaceutical was ₩405B at the close on Oct 28, 2026.
- Who are the largest shareholders of IL Dong Pharmaceutical?
- According to the latest official filings, the largest reported holders are Yun Won-young (34.50%, as of Feb 20, 2026); DB Ilban Best 3rd (4.62%, as of Jul 22, 2025); National Pension Service (2.30%, as of Dec 31, 2025).
- When is the next earnings report from IL Dong Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when IL Dong Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own IL Dong Pharmaceutical?
- Yes. The National Pension Service held 2.30% of IL Dong Pharmaceutical shares as of Dec 31, 2025.
Company profile
The company manufactures and sells pharmaceuticals, pharmaceutical raw materials, health supplements, and special nutritional foods. Its main pharmaceutical products include active vitamin products such as Aronamin-series, the antibiotic Furamarin, and other prescription and over-the-counter medicines. Products are sold through wholesalers, retailers, clinics, and general hospitals in Korea and abroad, and the company operates production facilities in Anseong and Cheongju, South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 일동제약
- Sector
- Biotech & Pharma
- CEO
- 윤웅섭, 이재준(공동 대표이사)
- Founded
- Aug 2016
- Listed
- Aug 2016
- Listed shares
- 31,638,252
- Fiscal year ends
- Month 12
- Website
- www.ildong.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
IL Dong Pharmaceutical Group and Nine & Company to Enter Beauty and Healthcare Market
Predicted impact: Low
Joint venture for beauty market; ownership change previously disclosed, no size given.
Ildong Pharmaceutical launches active vitamin combination 'Superamin', targeting pharmacy vitamin market
Predicted impact: Low· Actual: −5.1% vs sector, volume 0.6× normal (5 trading days)
Vitamin product launch in a small pharma market; no size or revenue impact given.
Recent filings
See all- Advance Notice of Earnings Results Disclosure (Informational Disclosure)Oct 28, 2026
- Acquisition of shares in another companySep 30, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Jul 30, 2026
- Fair Trade Self-Compliance Program Operation Status (Informational Disclosure)Jul 30, 2026
Titles in Korean until English translations are added.
Also known as: IL Dong Pharmaceutical / 일동제약 / 249420 / KRX:249420
Source: KRX statistical information